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.2012.03.Abstract Background: Burned patients exhibit resistant response to nondepolarizing muscle
relaxants. This study was designed to investigate the efﬁcacy of high dose atracurium (3 and 4 times
ED95) with and without application of the priming principle on the intubating conditions and the
onset times in burned patients.
Methods: ASA physical status I and II patients undergoing burn related surgery, were randomly
allocated into one of four groups of 20 patients each. Group I received 1 ml placebo followed
3 min later by atracurium 0.75 mg/kg, group II received atracurium 0.04 mg/kg as the priming dose
followed 3 min later by atracurium 0.71 mg/kg, group III received 1 ml placebo followed 3 min later
by atracurium 1 mg/kg and group IV received atracurium 0.04 mg/kg as the priming dose followed
3 min later by atracurium 0.96 mg/kg. Datex relaxograph was used at the adductor pollicis to mon-
itor and record the twitch response to the train of four (TOF) stimulation.
Results: The conditions for intubation improved signiﬁcantly with increasing the dose of atracuri-
um, as we seen, when comparing patients in group IV and group I. Onset times were signiﬁcantly
delayed in groups I and II compared with groups III and IV.
Conclusion: Combinations of 4 times ED95 of atracurium together with the application of the
priming principle are required to overcome the resistance and produce satisfactory intubating con-
ditions in burned patients.
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0011. Introduction
Patients with thermal injury usually demonstrate resistant
response to nondepolarizing muscle relaxants (NDMRs) and
this manifests itself clinically by increasing the dose of
NDMRs to produce the desired effect [1]. This type of resis-
tance usually seen when burn involves more than 20% of total
body surface area (TBSA). It was found that peri-junctional
proliferation and the expression of immature acetylcholineosting by Elsevier B.V. Open access under CC BY-NC-ND license.
206 A.A. Mohamed et al.receptors on the muscle membrane are the main causes of resis-
tance [2,3].
Succinylcholine is contraindicated in burned patients, as it
may be associated with life threatening hyperkalemia. Alterna-
tive methods can be used in patients with thermal injury to
produce faster onset of neuromuscular effect including; the
use of high dosage of NDMRs, the combination of two struc-
turally different NDMRs or the use of the priming principle
[4].
This study was conducted to compare the effect of high
dose atracurium (3 and 4 times ED95 (Effective Dose 95%))
with and without application of the priming principle on the
onset times and the intubating conditions in burned patients.
2. Patients and methods
The study protocol was reviewed and approved by local hospi-
tal ethics committee. Written informed consent was obtained
from each patient. Eighty ASA I and ASA II patients with his-
tory of burns more than 20% total body surface area(TBSA),
aged 20–60 years, undergoing burn-related surgery lasting
more than one hour, at 21–90 days after the injury, were en-
rolled in the study at Mansoura University burn and plastic
surgery center.
Patients with history of using drugs known to inﬂuence
neuromuscular transmission or those with any disorder of re-
nal, hepatic, neurological, neuromuscular, or cardiovascular
system were excluded from the study. Patients were also ex-
cluded if having history of asthma, difﬁcult intubation or
requiring a rapid sequence procedure.
Patients were premedicated using midazolam 0.04 mg/kg
I.V. Routine monitors were applied upon arrival to the operat-
ing theater including electrocardiogram, noninvasive arterial
blood pressure, and pulse oximetry. Datex relaxograph was
used at the adductor pollicis to monitor and record the twitch
response to the train of four (TOF) stimulation. All patients
were preoxygenated with 100% oxygen for 3 min before induc-
tion of anesthesia.
Patients were randomly assigned according to predeter-
mined randomization code to four equal groups. The studied
patients received atracurium either at 3 ED95 (groups I and
II) or 4 ED95 (groups III and IV) with and without priming
as follow; group I – received 1 ml normal saline given I.V.
(intravenously) simulating the priming dose (placebo with sal-
ine) followed 3 min later by atracurium 0.75 mg/kg I.V. over
75 s, group II – received atracurium 0.04 mg/kg I.V. as the
priming dose followed 3 min later by atracurium 0.71 mg/kg
I.V. over 75 s, group III – received 1 ml normal saline given
I.V. simulating the priming dose (placebo with saline) followed
3 min later by atracurium 1 mg/kg I.V. over 75 s and group IV
– received atracurium 0.04 mg/kg I.V. as the priming dose fol-
lowed 3 min later by atracurium 0.96 mg/kg I.V. over 75 s.
General anesthesia was induced in the studied groups with
propofol 1.5–2.5 mg/kg I.V. and fentanyl 1–2 lg/kg I.V. 3 min
after administration of the priming dose (atracurium or saline).
The patients in group I and II received (3 ED95)0.75 mg/kg
atracurium and those in group III and IV received (4
ED95)1 mg/kg atracurium.
Neuromuscular monitoring was initiated after obtaining
the control values by supramaximal stimulus square wave
stimuli applied to the ulnar nerve at 2 Hz with pulse width0.2 ms repeated every 15 s. After TOF stabilization, the muscle
relaxant was given as previously mentioned for each group.
After induction of anesthesia and while TOF monitoring
was established, the airway was maintained with oral airway.
Manual ventilation was performed with 100% oxygen via face-
mask. The end tidal CO2 was kept within the normocarbic
range during this period. Onset time was noted (the interval
from the end of muscle relaxant bolus injection until the max-
imal suppression of T1 %).
Two minutes after injection of the intubating dose, endotra-
cheal intubation was attempted by laryngoscopist who was
blinded to the induction technique. The condition of intubation
was assessed and scored on a scale described by Clarke and
Mirakhur. Possible tracheal intubation conditions were excel-
lent (jaw relaxed, vocal cords apart and immobile, no diaphrag-
matic movement), good (jaw relaxed, vocal cords apart and
immobile, some diaphragmatic movement), poor (jaw relaxed,
vocal cords moving and substantial diaphragmatic movement),
or inadequate (jaw not relaxed, vocal cords closed) [5].
Anesthesia was maintained with 100% oxygen and isoﬂou-
rane (1–1.5 MAC (Minimum Alveolar Concentration)), bo-
luses of the muscle relaxant (10% of the initial dose) with
25% recovery of response to T1 % and ventilation was con-
trolled by the Datex-Ohmeda ventilator to adjust end tidal
CO2 at (30–35 mmHg).
At the end of operation, the block was reversed with neostig-
mine and atropine mixture (2.5 mg neostigmine: 1 mg atropine)
through slow IV injection if TOF-ratio was less than 70%.
The heart rate (HR), mean arterial blood pressure (MABP)
were noted before administration of atracurium and 1, 5, 10,
15 and 20 min after intubation. An observer blinded to ran-
domization schedule recorded signs of histamine release such
as ﬂushing (redness >2 min) or presence of any hemodynamic
changes or bronchospasm.
2.1. Statistical analysis
The statistical analysis of data was done by using excel pro-
gram for ﬁgures and SPSS program statistical package for so-
cial science; SPSS Inc., Chicago, IL. The description of the
data was done in form of mean ± SD for quantitative data,
and frequency and proportion for qualitative data. The analy-
sis of data was done to test statistical signiﬁcant difference be-
tween groups. One way ANOVA was used to compare more
than two groups followed by post hoc least signiﬁcant differ-
ence (LSD) test if subtraction between two means givesPLSD
this means signiﬁcant difference between the two means. Chi
square test was used for qualitative data. P is considered signif-
icant if < or = 0.05 at conﬁdence interval 95%.
Power analysis was not performed to determine sample size
because we did not have preliminary data on onset, maximum
block and duration of atracurium in burned patients with dif-
ferent priming regimen. However this study could be consid-
ered an exploratory pilot study rather than a formal test of
hypothesis. The sample size of 80 (20 in each group) was cho-
sen arbitrarily.
3. Results
All groups were comparable with respect to age, sex, height,
weight, extent of burn injury and the time of the study after
Table 1 Demographic data of the four groups.
Group I Group II Group III Group IV
Age (years) 38.75 ± 9.8 35.25 ± 5.3 37.6 ± 8.3 39.3 ± 10.1
Sex (M/F) 13/7 14/6 12/8 13/7
Weight (kg) 77.9 ± 6.6 73.5 ± 7.7 80.3 ± 7.6 76.8 ± 5.9
Height (cm) 168.7 ± 5.5 167.8 ± 7.9 169.7 ± 4.5 171.8 ± 4.8
Burn areaa 31.8 ± 6.9 31.2 ± 6.4 30.5 ± 7.1 32.1 ± 6.7
Days since burn injury 32.9 ± 13.9 35.2 ± 16.6 33.7 ± 14.1 34.6 ± 15.3
Group I (3 ED95 without priming), group II (3 ED95 with priming), Group III (4 ED95 without priming), Group IV (4 ED95 with priming).
Values are mean ± SD or number. No signiﬁcant differences between groups (p> 0.05%).
a % Of total body surface area.
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groups I and II, compared with groups III and IV. The neuro-
muscular block obtained in groups I and II, was incomplete,
however, doses of atracurium in groups III and IV were sufﬁ-
cient to produce complete block (p< 0.001) (Table 2).
In all patients, the tracheas were intubated at the ﬁrst lar-
yngeoscopy, and intubating conditions were noted as excellent
in 8 (40%), 10 (50%), 12 (60%), and 15 (75%); good in 7
(35%), 8 (40%), 8 (40%), and 5 (25%) and poor in 5 (25%),
2 (10%), 0, and 0 in group I, II, III and IV respectively (Table
3). The conditions for intubation improved signiﬁcantly with
increasing the dose of atracurium when comparing patients
in group IV and group I (excellent in 15 of 20 versus excellent
in 8 of 20, p< 0.05).
The mean arterial blood pressure and the heart rate were
signiﬁcantly more at 1 min after intubation in all groups
(p< 0.05), but at 5 min and thereafter, they had come near
the baseline(Tables 4 and 5). Signs of histamine release were
noted in 27 patients (33.75%) in the form of cutaneous ﬂush-
ing. The incidence of cutaneous ﬂushing seemed to be dose
dependent (25% (5), 25% (5), 40% (8), and 45% (9)) for
groups I, II, III and IV respectively with no signiﬁcant differ-
ences among the four groups (p> 0.05%). No patient in the
studied groups, developed bronchospasm or hypotension (see
Table 6).
4. Discussion
The results of this study have conﬁrmed previous ﬁndings [6]
that giving priming dose shortly before a larger bolus dose im-
proved both onset of paralysis and the intubating conditions
compared with the same single bolus dose; as in group II
(0.04 + 0.71 mg/kg) versus group I (0.75 mg/kg) and group
IV (0.04 + 0.96 mg/kg) versus group III (1 mg/kg), however,
no statistically signiﬁcant difference exists between either
groups II and I or groups IV and III.Table 2 Onset of neuromuscular blockade after administration of
Group I Group II G
Onset time (s) 227.3 ± 4.4 217 ± 4.1 1
Maximm block (%) 97.7 ± 1.6 98.25 ± 1.1 1
Group I (3 ED95 without priming), group II (3 ED95 with priming), gro
Values are mean ± SD or number.
* Statistically signiﬁcant difference versus group I (p< 0.001).
 Statistically signiﬁcant difference versus group II (p< 0.001). Least sigThe priming dose of NDMRs is usually 20% of ED95. This
dose accelerates the onset of action and improves onset times
by 10–40% with the fewest side-effects [7]. In this study we
chose relatively small priming dose of atracurium 0.04 mg/kg
(16% of ED95) to avoid occurrence of any respiratory difﬁcul-
ties. No patient in the primed groups (II and IV) complained
of diplopia or any evidence of hypoventilation after receiving
the priming dose.
In the current study, priming interval was kept at 3 min
simply because, it was found that 3 min priming interval gave
the optimum intubating conditions and waiting for 5 min gave
no added beneﬁts [8].
In accordance with other studies [9], increasing the dose of
atracurium from 3 ED95 (0.75 mg/kg) to 4 ED95 (1 mg/kg)
accelerated the onset times signiﬁcantly in groups III and IV
(1 mg/kg) when compared with groups I and II (0.75 mg/kg).
We did not study the duration of action of high dose atrac-
urium as this was not the aim of our study and thus we limited
the study to burn related surgery lasting more than one hour
simply because Mirakhur et al., found that the duration of
high dose atracurium 1 mg/kg was about 57 min [10].
Regarding intubating conditions, no signiﬁcant differences
exist among groups apart from the intubating conditions in
group IV which were developed signiﬁcantly faster (4 times
ED95 with application of priming principle) when compared
with group I (3 times ED95 with no priming). This study is con-
sistent with previous studies showing that burned patients have
resistance to atracurium and this was evidenced by failure to ob-
tain complete neuromuscular block in groups I and II. Causes of
resistance to NDMRs in burned patients may be due to en-
hanced protein binding or increased clearance kinetics andmost
importantly upregulation of acetylcholine receptors [11].
The heart rate and the mean arterial blood pressure in-
creased in all groups signiﬁcantly at 1 min after intubation
due to the stress response, however, HR and MABP returned
near the base line at 5 min and this is consistent with anotheratracurium in the studied groups.
roup III Group IV P LSD
78.1,* ± 3.7 167.4,* ± 5.8 <0.001 38.9
00,* 100,* <0.001 1.75
up III (4 ED95 without priming), group IV (4 ED95 with priming).
niﬁcant difference (LSD).
Table 3 Intubating conditions 2 min after administration of atracurium.
Score Group I Group II Group III Group IV
Excellent 8 (40%) 10 (50%) 12 (60%) 15* (75%)
Good 7 (35%) 8 (40%) 8 (40%) 5 (25%)
Poor 5 (25%) 2 (10%) 0 (0%) 0 (0%)
Inadequate 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Group I (3 ED95 without priming), group II (3 ED95 with priming), group III (4 ED95 without priming), group IV (4 ED95 with priming).
Values are number or %.
* Statistically signiﬁcant difference versus group (p< 0.05).
Table 4 Heart rate (HR) changes before and after injection of atracurium.
Group I Group II Group III Group IV
Basal 72.5 ± 5.9 72.3 ± 6.1 73.3 ± 4.2 72.2 ± 6.4
1 min after intubation 83.1 ± 6.9* 84.4 ± 5.7* 85.2 ± 3.7* 86.6 ± 5.1*
5 min 75.2 ± 8.1 76.1 ± 6.5 73.1 ± 3.9 73.6 ± 6.9
10 min 74.4 ± 6.8 75.3 ± 6.4 74.2 ± 5.1 73.3 ± 5.8
15 min 75.1 ± 7.3 74.9 ± 5.9 73.3 ± 4.4 74.4 ± 5.4
20min 74.7 ± 7.8 74.8 ± 6.4 74.5 ± 3.8 73.8 ± 6.6
Group I (3 ED95 without priming), group II (3 ED95 with priming), group III (4 ED95 without priming), group IV (4 ED95 with priming).
Values are mean ± SD or number. Values are mean ± SD.
* Statistically signiﬁcant difference versus baseline reading (p< 0.05).
Table 5 Mean arterial blood pressure (MABP in mmHg) changes before and after injection of atracurium.
Group I Group II Group III Group IV
Basal 81.3 ± 8.4 80.8 ± 9.4 81.9 ± 9.5 80.3 ± 10.7
1 min after intubation 92.6 ± 7.4* 91.7 ± 6.9* 91.8 ± 8.1* 90.9 ± 7.9*
5 min 85.4 ± 6.9 84.6 ± 8.1 84.7 ± 8.2 85.2 ± 9.1
10 min 83.6 ± 7.1 84.5 ± 8.4 84.9 ± 8.9 85.7 ± 8.3
15 min 82.5 ± 8.6 83.6 ± 9.1 83.8 ± 7.8 84.5 ± 8.7
20 min 81.9 ± 7.6 84.4 ± 8.9 83.7 ± 9.1 83.9 ± 8.8
Group I (3 ED95 without priming), group II (3 ED95 with priming), group III (4 ED95 without priming), group IV (4 ED95 with priming).
Values are mean ± SD.
* Statistically signiﬁcant difference versus baseline reading (p< 0.05).
Table 6 Incidence of cutaneous ﬂushing after administration of atracurium in the studied groups.
Group I Group II Group III Group IV v2 p
Cutaneous ﬂushing 5 (25%) 5 (25%) 8 (40%) 9 (45%) 2.85 0.41
Group I (3 ED95 without priming), group II (3 ED95 with priming), group III (4 ED95 without priming), group IV (4 ED95 with priming).
Values are number or %. No signiﬁcant differences between groups (p> 0.05%). v2 = Chi square test.
208 A.A. Mohamed et al.study which reported no changes in the HR or the arterial
blood pressure when atracurium was given in a dose up to
1 mg/kg [10] and also as we injected the bolus dose of atracu-
rium over 75 s preventing signiﬁcant increase in the plasma his-
tamine release and this was in agreement with another study
done by Scott et al. [12].
Flushing is a cutaneous manifestation resulting from skin
histamine release and is not always associated with increased
plasma histamine level [13]. The incidence of ﬂushing in ourstudy was similar to those obtained by other authors at com-
parable doses and was dose related [10].
Limitation of this study, we did not examine the effects of
burn size and time after burn on the neuromuscular effects
of atracurium.
In conclusion, combinations of 4 times ED95 of atracurium
together with the application of the priming principle are re-
quired to overcome the resistance and produce satisfactory
intubating conditions in burned patients.
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